SCHEMBL13633842

SCHEMBL13633842

Cc1ccc2cccnc2c1NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKBIA P25963 3/20 0.68
RELA Q04206 3/20 0.68
SLC40A1 Q9NP59 6/20 0.62
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
TDP1 Q9NUW8 3/20 0.58
THRB P10828 1/20 0.58
BLM P54132 1/20 0.58
LMNA P02545 3/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
CASP3 P42574 1/20 0.48
RAB9A P51151 1/20 0.48
RUNX1 Q01196 1/20 0.48
CBFB Q13951 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633824 0.85 SLC40A1 (0.68) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633878 0.83 SLC40A1 (0.59) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633916 0.82 SLC40A1 (0.72) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633768 0.82 SLC40A1 (0.61) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633877 0.81 NFKBIA (1.00) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633844 0.81 SLC40A1 (0.59) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633855 0.80 NFKBIA (0.67) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL13633883 0.79 SLC40A1 (0.54) NFKBIARELASLC40A1KMT2AMEN1
SCHEMBL2055429 0.78 SLC40A1 (0.72) SLC40A1KMT2AMEN1TDP1LMNA
SCHEMBL13633912 0.77 GABRA1 (0.59) NFKBIARELASLC40A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A NFKBIA 980/4885RELA 4160/4885SLC40A1 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.